journal article·2017-02-17Open access

Bioactive PLGA–curcumin microparticle-embedded chitosan scaffold: in vitro and in vivo evaluation

Muthukumar Amirthalingam, Narayanan Kasinathan, Arul Amuthan, Srinivas Mutalik, M. Sreenivasa Reddy, Udupa Nayanabhirama

Abstract

Wound healing is a complex process affected by several factors. In the present work, novel biocompatible PLGA-curcumin microparticle-embedded chitosan scaffold was fabricated for wound-healing application. Process variables involved in the preparation of microparticles were optimized using design of experiment. Scanning electron microscopy (SEM) confirmed the porous nature of scaffold with embedded microparticles. A maximum release of 14% of the encapsulated curcumin was observed at 12th hour. Modified tube dilution method showed that scaffold significantly (p < 0.05) reduced multiplication of Staphylococcus aureus. More than 50% of the excised wound in rats healed in 4 days with an epithilization period of 18 days.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Wound Healing and Treatments · Nanocomposite Films for Food Packaging · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India;

Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India;

Department of Pharmacology, Melaka Manipal Medical College and Center for Integrative Medicine & Research, Manipal University, Manipal, Karnataka, India;

Directorate of Research, Manipal University, Manipal, Karnataka, India

References (25)

Show source-provided references
1. 10.1016/j.lfs.2014.08.01610.1016/j.lfs.2014.08.016 ↗
2. 10.3109/02652048.2015.102849610.3109/02652048.2015.1028496 ↗
3. 10.1016/j.eurpolymj.2012.12.00910.1016/j.eurpolymj.2012.12.009 ↗
4. 10.1128/AAC.00760-0810.1128/AAC.00760-08 ↗
5. 10.1016/j.ijpharm.2015.03.05210.1016/j.ijpharm.2015.03.052 ↗
6. 10.3389/fphys.2012.0032110.3389/fphys.2012.00321 ↗
7. 10.1615/CritRevTherDrugCarrierSyst.v29.i1.1010.1615/CritRevTherDrugCarrierSyst.v29.i1.10 ↗
8. Guideline ICHHT. 2009. Pharmaceutical development. Q8 (R2). As revised in August. 1-24.
9. 10.1177/002203450935912510.1177/0022034509359125 ↗
10. 10.3109/21691401.2013.85210110.3109/21691401.2013.852101 ↗
11. 10.1016/S0142-9612(03)00483-610.1016/S0142-9612(03)00483-6 ↗
12. Kasinathan N · Drug Deliv · 2015 · 23 · 1017
13. 10.3109/21691401.2015.105881010.3109/21691401.2015.1058810 ↗
14. 10.1016/j.ijfoodmicro.2010.09.01210.1016/j.ijfoodmicro.2010.09.012 ↗
15. 10.1016/j.nano.2014.09.00410.1016/j.nano.2014.09.004 ↗
16. 10.1016/j.ijpharm.2007.04.02510.1016/j.ijpharm.2007.04.025 ↗
17. Mozafari M. · Trends Biomater Artif Organs · 2014 · 28 · 124
18. 10.1155/2014/94865010.1155/2014/948650 ↗
19. 10.3390/ma202037410.3390/ma2020374 ↗
20. 10.1016/S0039-6109(05)70572-710.1016/S0039-6109(05)70572-7 ↗
21. 10.1016/S1995-7645(10)60045-410.1016/S1995-7645(10)60045-4 ↗
22. 10.1007/s00289005044810.1007/s002890050448 ↗
23. 10.1002/jbm.a.3041010.1002/jbm.a.30410 ↗
24. 10.1002/jbm.127010.1002/jbm.1270 ↗
25. 10.2754/avb20067502019710.2754/avb200675020197 ↗